In vitro evaluation of the antiviral activity of methylglyoxal against influenza B virus infection
In vitro evaluation of the antiviral activity of methylglyoxal against influenza B virus infection
复制标题
DOI：
10.5582/ddt.2016.01045
复制
发表时间：
2016-08-01
影响因子：
3.1
通讯作者：
Kobayashi, Nobuyuki
中科院分区：
文献类型：
--
作者：
Charyasriwong, Siriwan;Haruyama, Takahiro;Kobayashi, Nobuyuki
甲型和乙型流感病毒感染是全球严重的公共卫生问题。然而，对乙型流感感染的担忧被低估了。目前使用的抗流感药物对甲型流感病毒和乙型流感病毒的疗效并不相同。已观察到乙型流感病毒对神经氨酸酶（NA）抑制剂的易感性低于甲型流感病毒。此外，抗流感药物耐药性的出现强调了开发新药的必要性。最近，我们报道了甲基乙二醛（MGO）以菌株独立的方式抑制甲型流感病毒的复制。因此，我们假设MGO对B株具有抗流感活性。本研究旨在利用Madin-Darby犬肾（MDCK）细胞，评价MGO对乙型流感病毒的抗流感病毒活性。用几种乙型流感病毒检测了MGO的活性。比较了甲型流感病毒和乙型流感病毒对NA抑制剂的敏感性。MGO对B型流感病毒的复制有50%的抑制作用，抑制浓度在23 ~ 140 μ M之间，表明B型流感病毒的敏感性高于A型流感病毒。我们的研究结果表明，MGO对乙型流感病毒具有有效的抑制活性，包括NA抑制剂耐药株。
Influenza A and B virus infections are serious public health concerns globally. However, the concerns regarding influenza B infection have been underestimated. The currently used anti-influenza drugs have not provided equal efficacy for both influenza A and B viruses. Susceptibility to neuraminidase (NA) inhibitors has been observed to be lower for influenza B viruses than for influenza A viruses. Moreover, the emergence of resistance to anti-influenza drugs underscores the need to develop new drugs. Recently, we reported that methylglyoxal (MGO) suppressed influenza A virus replication in a strain-independent manner. Therefore, we hypothesize that MGO exhibits anti-influenza activity against B strains. This study aimed to evaluate the anti-influenza viral activity of MGO against influenza B strains by using Madin-Darby canine kidney (MDCK) cells. Several types of influenza B viruses were used to determine the activity of MGO. The susceptibilities of influenza A and B viruses to NA inhibitors were compared. MGO inhibited influenza B virus replication, with 50% inhibitory concentrations ranging from 23-140 mu M, which indicated greater sensitivity of influenza B viruses than influenza A viruses. Our results show that MGO has potent inhibitory activity against influenza B viruses, including NA inhibitor-resistant strains.